Hybrid Financial Services Regulatory Approval

Board Meeting Date

Hybrid Financial Services Board Meeting Date

Hybrid Financial Services will hold its Board on 2 Nov 2026 to consider unaudited Q1/H1 FY27 results. No financial figures are disclosed in this advance intimation.

Other Announcement

Hybrid Financial Services Other Announcement

Hybrid Financial Services Ltd has submitted its periodic shareholding pattern disclosure for the quarter ended September 30, 2026, in compliance with regulatory requirements.

Annual General Meeting

Hybrid Financial Services Annual General Meeting

Hybrid Financial Services filed the proceedings of its 39th AGM held 11 September 2026. Members approved the financials, a 1% preference dividend and a new whole-time director.

Business Update

Hybrid Financial Services Business Update

Hybrid Financial Services Limited has been admitted as a Trading Member in the Cash Segment by BSE Limited. This admission follows the merger of its subsidiary, Maximus Securities Limited, with the company.

Annual Report

Hybrid Financial Services Annual Report

Hybrid Financial Services Limited has released its 39th Annual Report for the financial year 2025-2026. The document includes the notice for the upcoming Annual General Meeting.

Financial Results

Hybrid Financial Services Q1 FY27 Results: Net Profit ₹0.6 Cr, Down 14.3% YoY

Hybrid Financial Services Ltd reported revenue from operations of ₹1.1 Cr (+10.0% YoY) and net profit of ₹0.6 Cr (-14.3% YoY) for Q1 FY27.

Key figure

Net profit ₹0.6 Cr · -14.3% YoY

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.